Current Metabolic Status Affects Urinary Liver-Type Fatty-Acid Binding Protein in Normoalbuminuric Patients With Type 2 Diabetes

Ito, Hiroyuki; Yamashita, Hiroyuki; Nakashima, Mina; Takaki, Akifusa; Yukawa, Chiduko; Matsumoto, Suzuko; Omoto, Takashi; Shinozaki, Masaru; Nishio, Shinya; Abe, Mariko; Antoku, Shinichi; Mifune, Mizuo; Togane, Michiko

doi:10.14740/jocmr2934w

Cited by 16 publications

(17 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies have proved that L-FABP is a promising biomarker of various kidney diseases as type 2 diabetes, vesicoureteral reflux, and B12 deficiency [21][22][23]. In the current study, urinary L-FABP was significantly higher in T1D subjects than in controls and also in the diabetic group it was significantly higher in microalbuminuric than in normoalbuminuric diabetic subjects.…”

Section: Discussionsupporting

confidence: 61%

Urinary liver-type fatty acid-binding protein as a Marker for Early Diagnosis of Diabetic Nephropathy in Type 1 Diabetic Children.

AbuShady

Fathy

et al. 2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objectives: Renal failure and premature mortality are fatal prognosis of diabetic nephropathy. To improve patient outcome, early diagnosis of diabetic nephropathy is necessary. The study was designed to evaluate urinary liver-type fatty acid binding protein (L-FABP), as an early biomarker of tubulointerstitial injury, and its association with the clinical characteristics of type 1 diabetic children.Methods: Fifty randomly selected patients with type 1 diabetes mellitus (DM) attending the diabetes outpatient clinic of Ain Shams University Children’s Hospital were included in the study. 50 age and sex-matched healthy subjects were enrolled as controls. Urinary L-FABP, 24 h urine albumin, hemoglobin A1c (HbA1c), serum creatinine, and lipid profile were measured.Results: Diabetic subjects had higher mean urinary L-FABP than controls (p<0.05). In microalbuminuric diabetic subjects, the mean urinary L-FABP was detected to be significantly higher than that in normoalbuminuric diabetic subjects, and significantly higher values of the mean urinary L-FABP were detected in the microalbuminuric and the normoalbuminuric subjects than the controls (p<0.05). Multiple linear regression analysis showed that duration of DM and HbA1c was the main predictors of urinary L-FABP in diabetic subjects.Conclusion: In patients with childhood-onset T1D, urinary L-FABP may be used as an indicator of renal injury in early stages of nephropathy, even in the normoalbuminuric state.

show abstract

Section: Discussionsupporting

confidence: 61%

Urinary liver-type fatty acid-binding protein as a Marker for Early Diagnosis of Diabetic Nephropathy in Type 1 Diabetic Children.

AbuShady

Fathy

et al. 2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

show abstract

“…We further classified all subjects into 2 groups: case group with 90 patients with DN and control group with 96 DM patients without DN, according to their 24-hour urinary albumin-to-creatinine ratio (ACR), blood urea nitrogen (BUN), and serum creatinine. [ 16 – 18 ] Patients who were classified as the case group fulfilled any of the following 3 criteria: the average ACR was >300 μg/mg; the BUN was >20 mg/dL; and the serum creatinine was >1.7 mg/dL. The rest of the patients were classified as the control group without DN.…”

Section: Methodsmentioning

confidence: 99%

Associations of TCF7L2 gene polymorphisms with the risk of diabetic nephropathy

Zhuang¹,

Niu²,

Liu³

et al. 2018

Medicine

View full text Add to dashboard Cite

The aim of the study was to explore the correlation between rs7903146 and rs290487 polymorphisms in transcription factor 7-like 2 (TCF7L2) gene and diabetic nephropathy (DN) in Chinese Han population.Polymerase chain reaction–restriction fragment length polymorphism was used to determine genotypes of TCF7L2 polymorphisms in 90 patients with DN and 96 diabetes patients without DN. The linkage disequilibrium (LD) and haplotype analysis were performed with haploview software. Hardy–Weinberg equilibrium was assessed in the control group based on the genotype distributions of TCF7L2 polymorphisms. The genotype, allele, and haplotype distribution differences between the case and control groups were analyzed by chi-squared test, and odds ratio (OR) and 95% confidence interval (CI) were used to indicate the relative risk of DN.People carrying TT genotype of rs7903146 were more easily to be attacked by DN than CC genotype carriers (P = .02, OR = 4.26, 95% CI = 1.12–16.24). Meanwhile, T allele also showed 1.85 times risk to suffer from DN compared with C allele (OR = 1.85, 95% CI = 1.02–3.10). However, there was no significant difference in genotypes and alleles frequencies of rs290487 between 2 groups. The strong LD existed between the 2 single nucleotide polymorphisms and haplotype T–T (rs7903146–rs290487) increased the susceptibility to DN (OR = 2.63, 95% CI = 1.31–5.25).TCF7L2 rs7903146 polymorphism may be associated with the susceptibility to DN in Chinese Han population, but rs290487 is not. Additionally, haplotype is also a risk factor for DN.

show abstract

“…The urinary L-FABP as well as uPE and uACR values were reduced by luseogliflozin in the present study, regardless of the eGFR at the baseline. While albuminuria reflects the glomerular injury in the kidneys, urinary L-FABP from proximal tubules is increased under conditions in which fatty acids are loaded into the proximal tubules, such as conditions of ischemia and exposure to nephrotoxic substances [37][38][39]. The interstitium, including the renal tubules but not the glomeruli, anatomically occupies most of the kidney, and tubulointerstitial injury is known to be more closely related to the renal prognosis than to glomerular lesions in patients with chronic kidney disease [46].…”

Section: Plos Onementioning

confidence: 99%

Different renoprotective effects of luseogliflozin depend on the renal function at the baseline in patients with type 2 diabetes: A retrospective study during 12 months before and after initiation

et al. 2021

Self Cite

View full text Add to dashboard Cite

Aims The safety and efficacy, particularly, the factors associated with the renal prognosis, were assessed over 12 months after the initiation of luseogliflozin therapy in Japanese patients with type 2 diabetes and renal impairment. Methods In total, 238 patients treated with luseogliflozin (2.5 mg, once daily) were studied as the safety analysis set. Two hundred and two subjects whose medication was continued over 12 months were investigated as the full analysis set. The subjects were divided into 3 groups based on the estimated glomerular filtration rate (eGFR): high eGFR (n = 49), normal eGFR (n = 116) and low eGFR (n = 37) groups. Results The body weight, systolic blood pressure, HbA1c and urinary protein excretion gradually decreased from baseline in all eGFR groups. While the eGFR was significantly reduced from baseline in the high and normal eGFR groups, the eGFR did not significantly differ over time in the low eGFR group. There was no marked difference in the frequency of adverse events that were specific for SGLT2 inhibitors among the 3 groups in the safety analysis set. Conclusions Luseogliflozin can preserve the renal function in the medium term in patients with type 2 diabetes and renal impairment without an increase in specific adverse events.

show abstract

Current Metabolic Status Affects Urinary Liver-Type Fatty-Acid Binding Protein in Normoalbuminuric Patients With Type 2 Diabetes

Cited by 16 publications

References 37 publications

Urinary liver-type fatty acid-binding protein as a Marker for Early Diagnosis of Diabetic Nephropathy in Type 1 Diabetic Children.

Urinary liver-type fatty acid-binding protein as a Marker for Early Diagnosis of Diabetic Nephropathy in Type 1 Diabetic Children.

Associations of TCF7L2 gene polymorphisms with the risk of diabetic nephropathy

Different renoprotective effects of luseogliflozin depend on the renal function at the baseline in patients with type 2 diabetes: A retrospective study during 12 months before and after initiation

Contact Info

Product

Resources

About